NVO FDA approves pluvicto for psma+ metastatic hormone-sensitive prostate cancer (mhspc), advancing potential new standard of Care across me
NVO FDA approves pluvicto for psma+ metastatic hormone-sensitive prostate cancer (mhspc), advancing potential new standard of Care across metastatic disease
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.